WO2000010977A1 - Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles - Google Patents
Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles Download PDFInfo
- Publication number
- WO2000010977A1 WO2000010977A1 PCT/US1999/018998 US9918998W WO0010977A1 WO 2000010977 A1 WO2000010977 A1 WO 2000010977A1 US 9918998 W US9918998 W US 9918998W WO 0010977 A1 WO0010977 A1 WO 0010977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- heterocycle
- group
- substituted
- alkali salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Definitions
- the present invention relates to the aminohydroxylation of olefins. More particularly, the present invention relates to the use of amino-substituted heterocycles as a nitrogen source for enantioselective aminohydroxylation reactions.
- a new generation of nitrogen sources is disclosed which greatly extends the scope of the osmium-catalyzed asymmetric aminohydroxylation (AA). With these nitrogen souices, the AA can now be considered as a means for introducing complex heterocyclic fragments into hydrocarbon backbones when approp ⁇ ate olefinic functionality is present.
- One aspect of the invention is directed to an improved method for converting an olefin to a ⁇ -aminoalcohol using an osmium-catalyzed asymmetric aminohydroxylation reaction.
- the olefin is enantioselectively aminohydroxylated using chiral hgands and an N-halo alkali salt of an ammo-substituted heterocycle as a nitrogen source for producing the ⁇ -aminoalcohol.
- the ammo group of the amino-substituted heterocycle is oxidized to form the N-halo alkali salt.
- the heterocycle of the ammo- substituted heterocycle includes a ring lmine conjugated with the amino group to form a planar imidamide system.
- the ⁇ -aminoalcohol produced by the catalytic asymmetric aminohydroxylation reaction has a ⁇ -amino group substituted with the heterocycle.
- the N-halo alkali salt of the amino-substituted heterocycle is represented by the following structure:
- X is a halogen
- Z + is an alkali counter ion
- -( ⁇ -X) " Z + represents the N-halo alkali salt
- -R 1 is one or more radicals, each independently selected from of hydrogen, halogen, aryl, and alkyl groups.
- Y does not include a fused imidazole ring that is coplanar with the planar imidamide system.
- the N-halo alkali salt of the amino-substituted heterocycle is obtained by oxidation of the following amino-substituted heterocycles:
- each R is independently selected from hydrogen, halogen, alkyl, aryl or, together with an adjacent R group, forms a fused aromatic ring.
- Figure 1 illustrates an aminohydroxylation with a generalized amino-substituted heterocycle.
- Figure 2 illustrates the aminohydroxylation with exemplary amino-substituted heterocycles.
- Figure3 illustrates the aminohydroxylation of stilbene with various amino- substituted-heterocycles. Footnotes therein are as follows: [a] Major product from the reaction using (DHQ) 2 PHAL. [b] Isolated yields of pure products after chromatography on silica gel. [c] Determined by chiral HPLC. [d] Concentration in grams per 100 mL of EtOH/CHCl 3 1:1.
- Figure 4 illustrates the aminohydroxylation of various olefins with 2-amino-4,6- dimethyltriazine. Footnotes therein are as follows: [a] Major product from the reaction using (DHQ) 2 PHAL. [b] Determined by ⁇ NMR spectroscopy. [c] Determined by chiral HPLC. [d] Isolated yields from the reaction using the (DHQ) 2 PHAL ligand, where regioisomers are possible, of mixture of both regioisomers. Similar yields and regioselectivities were obtained with the (DHQD) 2 PHAL ligand.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56822/99A AU5682299A (en) | 1998-08-21 | 1999-08-20 | Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9743898P | 1998-08-21 | 1998-08-21 | |
US60/097,438 | 1998-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000010977A1 true WO2000010977A1 (en) | 2000-03-02 |
WO2000010977A9 WO2000010977A9 (en) | 2000-12-14 |
Family
ID=22263347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/018998 WO2000010977A1 (en) | 1998-08-21 | 1999-08-20 | Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5682299A (en) |
WO (1) | WO2000010977A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006108713A2 (en) * | 2005-04-14 | 2006-10-19 | Schering Aktiengesellschaft | 1-amino-1, 2,3,4-tetrahydro-naphthaline-2-ol derivates as anti-inflammatory agents |
EP1878717A1 (en) * | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7659297B2 (en) | 2003-10-08 | 2010-02-09 | Bayer Schering Pharma, AG | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7880042B2 (en) | 2006-03-15 | 2011-02-01 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics |
EP2327700A1 (en) * | 2009-11-21 | 2011-06-01 | Bayer CropScience AG | Dialkyl triazinamines and use thereof for combating undesired plant growth |
US8097627B2 (en) | 2004-04-05 | 2012-01-17 | Bayer Pharma AG | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US8394958B2 (en) | 2007-11-22 | 2013-03-12 | Bayer Pharma AG | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
US8987504B2 (en) | 2010-06-18 | 2015-03-24 | Victoria Link Limited | Aminohydroxylation of alkenes |
-
1999
- 1999-08-20 WO PCT/US1999/018998 patent/WO2000010977A1/en active Application Filing
- 1999-08-20 AU AU56822/99A patent/AU5682299A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
DRESS K.R. ET AL: "Catalytic Aminohydroxylation Using Adenine-Derivatives as the Nitrogen Sources", TETRAHEDRON LETTERS, vol. 39, 1998, pages 7669 - 7672, XP002922720 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7659297B2 (en) | 2003-10-08 | 2010-02-09 | Bayer Schering Pharma, AG | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US8097627B2 (en) | 2004-04-05 | 2012-01-17 | Bayer Pharma AG | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
WO2006108713A3 (en) * | 2005-04-14 | 2006-12-14 | Schering Ag | 1-amino-1, 2,3,4-tetrahydro-naphthaline-2-ol derivates as anti-inflammatory agents |
WO2006108713A2 (en) * | 2005-04-14 | 2006-10-19 | Schering Aktiengesellschaft | 1-amino-1, 2,3,4-tetrahydro-naphthaline-2-ol derivates as anti-inflammatory agents |
US7880042B2 (en) | 2006-03-15 | 2011-02-01 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics |
US8173676B2 (en) | 2006-07-14 | 2012-05-08 | Bayer Pharma AG | Benzyl, amines, a process for their production and their use as anti-inflammatory agents |
EA015258B1 (en) * | 2006-07-14 | 2011-06-30 | Байер Шеринг Фарма Акциенгезельшафт | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
US7999108B2 (en) | 2006-07-14 | 2011-08-16 | Bayer Schering Pharma Ag | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
WO2008006627A1 (en) * | 2006-07-14 | 2008-01-17 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
EP1878717A1 (en) * | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
US8461346B2 (en) | 2006-07-14 | 2013-06-11 | Bayer Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
US8394958B2 (en) | 2007-11-22 | 2013-03-12 | Bayer Pharma AG | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
US8680117B2 (en) | 2007-11-22 | 2014-03-25 | Bayer Schering Pharma Ag | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
USRE47047E1 (en) | 2007-11-22 | 2018-09-18 | Astrazeneca Ab | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
EP2327700A1 (en) * | 2009-11-21 | 2011-06-01 | Bayer CropScience AG | Dialkyl triazinamines and use thereof for combating undesired plant growth |
US8987504B2 (en) | 2010-06-18 | 2015-03-24 | Victoria Link Limited | Aminohydroxylation of alkenes |
Also Published As
Publication number | Publication date |
---|---|
WO2000010977A9 (en) | 2000-12-14 |
AU5682299A (en) | 2000-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chuentragool et al. | General, mild, and selective method for desaturation of aliphatic amines | |
Grange et al. | Recent developments in asymmetric allylic amination reactions | |
Blank et al. | An efficient method for the selective Iridium‐catalyzed monoalkylation of (hetero) aromatic amines with primary alcohols | |
JP5738185B2 (en) | Process for preparing amines from alcohols and ammonia | |
WO2000010977A1 (en) | Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles | |
Goossen et al. | Catalytic Asymmetric Aminohydroxylation with Amino‐Substituted Heterocycles as Nitrogen Sources | |
Banik et al. | Samarium-induced iodine-catalyzed reduction of imines: synthesis of amine derivatives | |
Park et al. | A general strategy for the synthesis of indoloquinolizine alkaloids via a cyanide-catalyzed imino-Stetter reaction | |
Bartoccini et al. | Total synthesis of (−)-clavicipitic acid via γ, γ-dimethylallyltryptophan (DMAT) and chemoselective C–H hydroxylation | |
SK284369B6 (en) | Bisphosphine derivatives, their complexes and method of production of bisphosphine derivatives | |
CN109096174A (en) | A kind of synthetic method of unsubstituted [60] fulleropyrrolidine derivative of N- alkyl -2,5- | |
Kiselyov | A novel three-component reaction of N-fluoropyridinium salts: a facile approach to imidazo [1, 2-a] pyridines | |
Vyskočil et al. | On the ‘Novel two-phase oxidative cross-coupling of the two-component molecular crystal of 2-naphthol and 2-naphthylamine’ | |
CN108640944B (en) | Conjugated eneyne amide compounds and preparation method and application thereof | |
Stolle et al. | Intramolecular Diels-Alder reactions of pyrimidines and a computational study toward their structure and reactivity | |
CN113004248B (en) | Method for synthesizing carbazole compound by catalyzing hydrocarbon amination reaction with cobalt | |
US10995056B2 (en) | Direct C—H amination and aza-annulation | |
CN107298683B (en) | A kind of synthetic method of chirality benzodiazepine * compound | |
CN115197145B (en) | Chiral spiro ammonium salt compound and preparation method and application thereof | |
CN101090881A (en) | Process | |
Kuliukhina et al. | CuI and Copper Nanoparticles in the Catalytic Amination of 2-Halopyridines | |
Doğan et al. | PFAM catalyzed enantioselective diethylzinc addition to imines | |
Zhou et al. | Substitution‐type Electrophilic Amination Using Hydroxylamine‐Derived Reagents | |
Cho et al. | Ruthenium‐Catalyzed synthesis of quinolines from anilines and N‐allylic compounds by cascade amine exchange reaction‐heteroannulation | |
CN102718714B (en) | Anthracene-bridged tetradentate imidazole salt and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |